RBC Capital Cuts argenx (ARGX) Price Target to $1,025
Key Points
- RBC Capital kept its Outperform rating on argenx SE on October 20, 2026, reducing its target price to $1,025 from $1,100.
- RBC Capital's $1,025 price target implies 17.27% upside from argenx SE's ($ARGX) current $874.08 share price.
- Jupiter Topco LLC grew its holdings by 1,237,008 shares to end with 2,474,015 shares valued at about $2.17 billion.
- The biopharma company trades near $874.08, sitting below its 50-day moving average ahead of its October 22, 2026 earnings release.
Get argenx SE text alerts
We text you when insiders, Congress, analysts or big funds move on $ARGX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
On October 20, 2026, RBC Capital maintained its Outperform rating on argenx SE while adjusting its price target down to $1,025 from $1,100. The research note outlines the firm's updated expectations for the biotechnology company as shares trade near the $874.08 mark.
ARGX
argenx SE
RBC Capital vs. the S&P 500
Hypothetical returns from RBC Capital's disclosed trades, not real profit or advice. How we model this.
RBC Capital's Call on argenx SE
RBC Capital kept its Outperform rating on argenx SE on October 20, 2026, lowering its target price to $1,025 from $1,100. The adjustment follows a series of updates from Wall Street firms reviewing the drug developer's valuation ahead of its upcoming financial results.
Other Institutional Activity in argenx SE
Jupiter Topco LLC grew its holdings by 1,237,008 shares, ending with 2,474,015 shares worth about $2.17 billion. Artisan Partners Limited Partnership lifted its stake by 40,810 shares, finishing with 1,508,778 shares valued at roughly $1.32 billion. Avoro Capital Advisors LLC kept its holdings steady at 1,000,000 shares worth about $875.9 million. RTW Investments LP also maintained its position, holding 709,446 shares valued at roughly $621.4 million.
argenx SE Stock Up 5.9%
Shares of argenx SE recently traded around $874.08, down about 0.2% from their closing price of $875.93 on October 20, 2026. The stock sits below its 50-day moving average of $952.08 but remains above its 200-day moving average of $851.30. Over the past year, the shares have traded between a low of $661.85 and a high of $1,072.75.
$ARGX price target
argenx SE daily closes and this analyst's $1,025 target. Not advice.
Recent Earnings
The company generated $5.32 billion in trailing revenue with earnings of $26.24 per share. Its net profit margin stands at 32.3% alongside a return on equity of 23.6%. Investors will examine fresh financial data when the company releases its next earnings report on October 22, 2026.
Analysts Set New Price Targets
Evercore ISI Group maintained an Outperform rating on October 9, 2026, lowering its target to $1,078 from $1,175. Baird kept a Neutral rating on October 9, 2026, cutting its target to $823 from $932. Oppenheimer maintained an Outperform rating on October 12, 2026, moving its target to $1,038 from $1,100. Wells Fargo kept an Overweight rating on October 14, 2026, adjusting its target to $1,356 from $1,355. Analysts overall hold a consensus buy recommendation on the stock.
About argenx SE
Based in Amsterdam, argenx SE focuses on developing antibody-based therapies for autoimmune diseases. Its commercial portfolio features treatments such as VYVGART and VYVGART HYTRULO for conditions including generalized myasthenia gravis and immune thrombocytopenia.
Bottom Line
Market participants are tracking how institutional investors adjust their positions ahead of the October 22, 2026 earnings release. Analysts continue to review price targets across the healthcare sector as firms update their outlooks.
Related Filing Alerts
Source: RBC Capital's rating change on $ARGX (Oct 20, 2026). Written by software, not financial advice. How we make alerts